Terms: = Prostate cancer AND RMI2, MGC24665, 116028, C16orf75, ENSG00000175643
4 results:
1. rmi2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma.
Li Y; He X; Zhang X; Xu Y; Chen W; Liu X; Xu X
Clin Exp Med; 2022 May; 22(2):229-243. PubMed ID: 34275027
[TBL] [Abstract] [Full Text] [Related]
2. Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant cancer Cells.
Uddin MH; Li Y; Khan HY; Muqbil I; Aboukameel A; Sexton RE; Reddy S; Landesman Y; Kashyap T; Azmi AS; Heath EI
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206543
[TBL] [Abstract] [Full Text] [Related]
3. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine prostate cancer.
Zhang W; Liu B; Wu W; Li L; Broom BM; Basourakos SP; Korentzelos D; Luan Y; Wang J; Yang G; Park S; Azad AK; Cao X; Kim J; Corn PG; Logothetis CJ; Aparicio AM; Chinnaiyan AM; Navone N; Troncoso P; Thompson TC
Clin Cancer Res; 2018 Feb; 24(3):696-707. PubMed ID: 29138344
[No Abstract] [Full Text] [Related]
4. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC
Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297
[TBL] [Abstract] [Full Text] [Related]
